What are the common side effects of Datopotamab?

As a new generation of TROP2 targeting ADC drugs datopotamab (Datopotamab) is better than some traditional chemotherapy regimens in terms of overall tolerability, but it will still be accompanied by specific adverse reactions related to its drug structure and mechanism of action. Because it uses antibodies to accurately deliver cytotoxic payloads, side effects are more affected by factors such as target expression, payload type, and tissue exposure.

Multiple studies have shown that the most common side effects are concentrated in the gastrointestinal tract, skin system and respiratory system, among which nausea, oral mucosal discomfort, fatigue and mild to moderate rash are more typical. This type of reaction is usually related to drug exposure in mucosal tissue and is a common toxicity manifestation of ADC drugs.

Skin reactions may occur in some patients, including dryness, itching or local inflammation, which is related to the low expression of TROP2 in some normal tissues. Most skin reactions are manageable and can be alleviated with topical care, moisturizing, and adjusting the pace of treatment when necessary. Respiratory discomfort such as mild cough or respiratory tract irritation has also been reported in some patients. It usually occurs in the early stages of treatment and is related to systemic exposure of the drug. Most of them are transient manifestations.

Ocular symptoms are also a reaction category of concern with ADC drugs and include blurred vision or mild eye irritation, which is related to the possible effects of the payload component on surface cells, so regular ophthalmological evaluation is recommended during treatment. Gastrointestinal reactions such as nausea, abdominal discomfort, and loss of appetite are common and can generally be alleviated through dietary modification and symptomatic treatment.

Overall, most of the adverse reactions of dabrotomab are controllable, but it still needs to be used regularly under the supervision of the medical team and the treatment strategy adjusted according to personal tolerance. For patients who have received multiple lines of treatment, the acceptable risk range is relatively clear, and the side effects management methods are relatively mature, making it a good application potential in the field of solid tumors.

Reference materials: https://www.google.com.hk/